Clinicopathological Characteristics and Prognosis of Pediatric Immunoglobulin A Nephropathy: A Follow-up Exceeding 10 Years

Technical Summary: Clinicopathological Characteristics and Prognosis of Pediatric Immunoglobulin A Nephropathy

Problem Statement
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis globally, with a particularly high prevalence in East Asia. While pediatric IgAN is often considered to have a more favorable prognosis than adult-onset disease, recent evidence suggests a significant lifetime risk of progression to chronic kidney disease (CKD) stage 5, even in children presenting with mild initial symptoms. A critical limitation in the existing literature is the scarcity of long-term follow-up data; most studies are constrained by relatively short observation periods. Consequently, there is a need to characterize the clinicopathological trajectories and identify robust prognostic factors for pediatric IgAN over a decade or more to inform clinical management and risk stratification.

Methodology
This study employed a retrospective cohort design involving 50 pediatric patients (age ≤18 years) diagnosed with primary IgAN via kidney biopsy at the Children's Hospital Affiliated to Capital Institute of Pediatrics between 2007 and 2015. The inclusion criteria required complete clinical data and a follow-up duration of at least 10 years.

• Data Collection: Researchers gathered baseline clinical characteristics (e.g., hematuria, hypertension, nephrotic-range proteinuria), laboratory parameters (eGFR, serum albumin), and detailed pathological data. Pathological assessment included light microscopy, immunofluorescence, and electron microscopy, graded according to the Lee classification and the Oxford MEST-C classification (2009).
• Endpoints: Patients were stratified into "endpoint" and "non-endpoint" groups based on a composite endpoint: progression to CKD stage 5 or a ≥30% decline in estimated glomerular filtration rate (eGFR) from baseline.
• Subgroup Analysis: Among patients with nephrotic-range proteinuria, a secondary analysis compared outcomes between those receiving high-dose methylprednisolone pulse therapy and those receiving non-high-dose regimens.
• Statistical Analysis: Continuous variables were compared using t-tests or Wilcoxon rank-sum tests, while categorical variables were analyzed using chi-square or Fisher's exact tests. Cumulative kidney survival was estimated using the Kaplan–Meier method with log-rank testing.

Key Results
The median follow-up duration was 12.9 years. The study yielded the following primary findings:

1. Long-term Prognosis: The overall prognosis was favorable, with 82.0% of patients achieving sustained clinical remission. However, 6.0% (3 out of 50) of patients progressed to CKD stage 5 at 3, 10, and 14 years post-biopsy, respectively.
2. Predictors of Poor Outcome: The endpoint group (progression to CKD stage 5 or significant eGFR decline) was significantly associated with:
   • Failure to achieve proteinuria remission at 6 months post-treatment (P = 0.027).
   • The presence of T1 lesions (tubular atrophy/interstitial fibrosis involving 26–50% of the cortical area) on kidney biopsy (P = 0.002).
   • A lack of immunoglobulin M (IgM) positivity on immunofluorescence (P = 0.016).
   • No significant differences were observed regarding sex, age, gross hematuria, hypertension, baseline eGFR, or M/E/S/C lesions between the groups.
3. Therapeutic Response in Nephrotic-Range Proteinuria: In the subgroup of patients with nephrotic-range proteinuria, those who received high-dose methylprednisolone pulse therapy had a significantly higher cumulative clinical remission rate at the end of follow-up compared to those on non-high-dose regimens (P = 0.031). Notably, the high-dose group presented with more severe baseline pathology (higher rates of Lee Grade ≥III and S1 lesions), suggesting clinicians selected pulse therapy for more severe cases.
4. Risk Prediction Tools: The application of an international pediatric IgAN prognostic prediction tool showed a trend toward higher risk scores in the endpoint group, though the difference was not statistically significant (P = 0.265), likely due to the small sample size of the endpoint group.

Significance and Claims
The authors claim that this study addresses a critical gap in pediatric IgAN research by providing data from a follow-up period exceeding 10 years. The primary significance of the work lies in confirming that while most pediatric IgAN patients maintain favorable long-term outcomes, a subset faces significant risk of progression.

The paper asserts that failure to achieve proteinuria remission within 6 months and the presence of T1 lesions are critical, modifiable, and non-modifiable risk factors, respectively, for poor long-term outcomes. Furthermore, the study suggests that early intensive immunosuppressive therapy (specifically high-dose methylprednisolone pulse therapy) may improve clinical remission rates in children with nephrotic-range proteinuria and severe pathological activity.

The authors conclude that long-term monitoring and risk stratification are essential. They emphasize that achieving early complete remission and ensuring treatment adherence are vital for improving long-term kidney survival. Additionally, the study highlights the potential role of family history and genetic susceptibility in disease progression, suggesting these factors warrant careful assessment in clinical practice. The modest statistical power regarding the prognostic prediction tool indicates a need for larger, multicenter cohorts to refine individualized risk prediction models.